Silo pharma issues letter to shareholders detailing development progress and potential for lead assets targeting ptsd and chronic pain

Sarasota, fl, jan. 02, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” “we,” “us,” “our,” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today issued a letter to shareholders highlighting the company's progress and potential for its lead assets spc-15 and sp-26 as treatments for mental health and chronic pain management, respectively. the letter, in its entirety, is reprinted below.
SILO Ratings Summary
SILO Quant Ranking